Kornimate/medical-research-clean huggingface dataset:
thyroid dysfunction in head and neck surgery patients

Conditions: Thyroid Dysfunction

Summary: specific aim i: determine absorption of iodine after oropharyngeal application of povidone-iodine 10% solution when used in head and neck surgery involving the upper aero-digestive tract. specific aim ii: measurement of iodine induced changes in thyroid function.

serial blood draws will be obtained from approximately 10 men and women age 18 and over who have been exposed to intraoperative oropharyngeal application with povidone-iodine 10%. baseline serum and 24-hour urine iodine levels will be measured preoperatively. serum iodine levels will be drawn at 1 hour, 2 hours, 4 hours, 6 hours, 24 hours, 1 week, and 1 month after exposure. a postoperative 24-hour urine iodine level will also be obtained. with the above measurements, the amount of iodine absorption as well as the time period of peak absorption and duration of elevated iodine levels will be elucidated. thyroid hormone metabolism is highly dependent on serum levels of iodine. thyroid function will be assessed by measuring serum levels of free thyroxine, free triiodothyronine, and thyroid stimulating hormone also at 1 hour, 2 hours, 4 hours, 6 hours, 24 hours, 1 week, and 1 month after exposure. measuring thyroid function is important since hypothyroidism has been known to have a major impact on postoperative wound healing.

Eligibility criteria:
inclusion criteria: * patients undergoing any head and neck surgery requiring entry into the upper aerodigestive tract and thus necessitating the oral administration of the antimicrobial agent povidone-iodine 10%. exclusion criteria: * patients with history of hypothyroidism currently taking thyroid hormone medications (i.e. synthroid, levothyroxine, thyroxine) and women who are pregnant.

Keywords: patients undergoing head and neck surgery that involves the upper aerodigestive tract
comparison of av optimization methods used in cardiac resynchronization therapy (crt)

Conditions: Heart Failure

Summary: the primary objective of smart-av is to assess the effect of smartdelay for determining optimal av delay timing during crt compared to both a fixed av delay and echocardiography-determined optimal av timing chronically over a 6-month period.

smart-av is a randomized, multi-center, double-blinded, non-significant risk, three-armed trial that will investigate the effects of optimizing av delay timing in heart failure patients receiving crt-d therapy. patients will be randomized in a 1:1:1 ratio using randomly permuted blocks within each center. the study will compare chronic changes in structural and functional outcomes in crt-d patients randomized to av delay set as fixed, set with smartdelay or determined by echocardiography. patients will be followed at enrollment, implant, post-implant, 3-months post-implant and 6-months post-implant.

Eligibility criteria:
inclusion criteria: * patients who meet current indications for a bsc crt-d device with the smartdelay algorithm * patients who are willing and capable of undergoing a device implant and participating in all testing associated with the smart-av study * patients who are on optimal and stable pharmacologic therapy * patients who are expected to be in sinus rhythm at the time of implant * patients who have a life expectancy of more than 360 days, per physician's discretion * patients who are geographically stable and willing to comply with the required follow-up schedule * patients who are 18 years of age or above, or of legal age to give informed consent specific to state and national law exclusion criteria: * patients who are in complete heart block, or who otherwise are unable to tolerate pacing at vvi-40 rv for up to 14 days * patients undergoing an upgrade of a pacemaker or implantable cardioverter-defibrillator who are unable to tolerate pacing at vvi-40 rv for up to 14 days * patients who have previously received cardiac resynchronization therapy * patients who are expected to receive a heart transplant or have other cardiac surgeries or procedures planned during the course of the study * patients who currently have or who are likely to receive a tricuspid valve prosthesis * patients who have a neuromuscular, orthopedic, or other non-cardiac condition that prevents normal, unsupported walking * patients who are pregnant or planning to become pregnant during the study * patients who are currently enrolled in another investigational study or registry that would directly impact the treatment or outcome of the current study

Keywords: heart failure hf cardiac resynchronization therapy crt optimization smartdelay echocardiography av delay
study for the treatment of ulcerative colitis with adacolumn (companion to us study 512-04-205)

Conditions: Ulcerative Colitis

Summary: the purpose of the study is to demonstrate the safety and effectiveness of the adacolumn apheresis system to treat the signs and symptoms of ulcerative colitis.

study type: interventional study design: treatment, randomized, double-blind, placebo control, parallel assignment, safety/efficacy study.

Eligibility criteria:
a comparison of cpr outcomes between traditional and endomorphic manikins with and without equipment

Conditions: Cardiac Arrest

Summary: the study's research design is a randomized experiment. 50 emergency responders (emergency medical responders, emergency medical technicians, advanced emergency medical technicians, and paramedics) will be recruited for this research. all data collection will take place in lab 14 of the benson bunker fieldhouse or a professional, confidential location of the participant's choosing. prior to cpr performance, participants will be given an informed consent form to sign. the form will be explained in detail by the researcher collecting data. after obtaining informed consent, participants will be asked to fill out a demographic questionnaire to collect information such as age, gender, years of emergency responder experience/employment, and years of cpr certification. demographic information provided by participants will be utilized in data analysis. the demographics form should take approximately five minutes to complete. participants will be randomly assigned to the four trials they will partake in and instructed via oral script (one for over and one for under football shoulder pads) to perform four-trials total of three-minute single-rescuer cpr on both a traditional cpr manikin and "fat old fred" (bariatric) cpr manikin. cpr must be performed in accordance with the american heart association's 2015 cpr guidelines and participants will use a cprmeter 2 device to collect data to determine the quality of cpr components (chest compression depth/recoil, compression rate, cpr compression duration, mean depth, mean rate, and total number of compressions). the entire study session should take 25 to 30 minutes to complete.


Eligibility criteria:
inclusion criteria: * emergency responders employed through the ambulance stations located in north dakota and minnesota * current cpr/first-aid certification * active clinician, educator, or administrator. exclusion criteria: * cardiovascular conditions inhibiting cpr performance * respiratory conditions inhibiting cpr performance * musculoskeletal conditions inhibiting cpr performance
association between cgm metrics in type 2 diabetes pregnancy and perinatal morbidity

Conditions: Type 2 Diabetes Mellitus (T2DM); Pregnancy

Summary: the purpose of this observational study is to measure the association between continuous glucose monitoring (cgm) parameters and perinatal morbidity in offspring of women with type 2 diabetes. specifically, the study will assess whether gestational age interacts with metabolic control in influencing perinatal morbidity, as well as the impact of the timing of cgm initiation during pregnancy.

continuous glucose monitoring (cgm) data in pregnant women living with type 2 diabetes (t2d) and its association with perinatal morbidity are very recent and remain scarce. moreover, perinatal morbidity appears to differ in these patients compared to pregnancies affected by type 1 diabetes or gestational diabetes. as a result, a deeper understanding is needed to identify the most relevant glycemic parameters and, in particular, the gestational age most critical for metabolic control. furthermore, uncertainty remains regarding the benefits of early cgm use in this population, which is characterized by early-onset t2d. a description of this population in the french context is therefore of particular interest. this single-centre observational study will consist of a retrospective cohort of patients with type 2 diabetes and pregnancy with pregnancy follow-up and delivery at the centre hospitalier sud-francilien between 1 january 2020 and 31 january 2025.

Eligibility criteria:
inclusion criteria: * adult patient * patient diagnosed with type 2 diabetes before or during pregnancy (fasting blood glucose \> 126 mg/dl, blood glucose \> 200 mg/dl after an oral glucose tolerance test, or hba1c \> 6.5%) * patient who has undergone continuous glucose monitoring at least once during pregnancy exclusion criteria: * multiple pregnancy * pregnancy terminated before 20 weeks of amenorrhea * delivery outside chsf * patient and/or legal guardians of the newborn who objected to the use of data

Keywords: type 2 diabetes mellitus continuous glucose monitoring pregnancy retrospective cohort study
satellite-supplementation of medical outreach clinics: a feasibility study

Conditions: Telemedicine; Primary Health Care; Developing Countries; Diagnosis; Therapeutics

Summary: much of the basic general medical care and chronic disease management in rural honduras comes from groups of volunteers setting up temporary clinics run by volunteers. these clinics, also known as brigades, or medical missions, are often criticized for their lack of quality and the lack of follow-up, both of which stem, in part, from understaffing with volunteer physicians. this study is designed to assess if it is feasible, safe, and acceptable to treat patients in short-term mobile medical clinics in rural honduras using us physicians connected with patients by videoconference.


Eligibility criteria:
inclusion criteria: * able to give informed consent * non-emergent medical complaints * at least 18 yrs in age exclusion criteria: * pregnancy * mental disability

Keywords: diagnostic concordance treatment concordance patient satisfaction physician satisfaction medical outreach clinics medical brigades medical missions telemedicine videoconference diagnoses treatments satellite internet vsat cross cultural telemedicine
healthier living canada

Conditions: Asthma; Chronic Disease

Summary: this study will evaluate the effectiveness of an online chronic disease self-management program for participants in canada living with chronic health conditions. this pilot will look for improvements in health status, health behaviors and health care utilization.

the healthier living with ongoing health problems online workshop provides self-management and self care skills training for people with long-term health conditions such as heart disease, lung disease, diabetes, multiple sclerosis, asthma and others. the workshop is delivered via the internet over a six-week period. this is a pilot project, which means that it is being run for a limited time to test out its format and its usefulness for participants in canada. a similar programme has been implemented in the usa, uk, and australia, but it has to be tried now in canada to see its usefulness for people in this country. . the online workshop is aimed at helping you to take better care of yourself and to better manage your health condition. it is hoped that at the end of the workshop you will be able to do the things you want to do and maintain the relationships that are important to you. with the facilitators and other workshop participants, you will discuss: * dealing with fatigue/tiredness * dealing with difficult emotions * dealing with your physical symptoms * solving the problems caused by your condition * starting and maintaining an appropriate exercise or activity programme * managing medications * communicating better with health care professionals * communicating better with your friends, family and colleagues

Eligibility criteria:
inclusion criteria:adults 18 and over living with any chronic or long term health condition such as heart disease, lung disease, diabetes. exclusion criteria:not meeting the inclusion criteria
a study of intraocular pressure (iop) reduction in newly diagnosed patients with primary open angle glaucoma (poag) or ocular hypertension (oht)

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this is an observational study and will evaluate iop reduction in newly diagnosed patients with poag or oht. all care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.


Eligibility criteria:
inclusion criteria: * newly diagnosed with primary open angle glaucoma or ocular hypertension exclusion criteria: * none
compare the effects of bifeprunox and quetiapine on weight changes in stable schizophrenic patients

Conditions: Schizophrenia

Summary: the primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. study participation for the subject is 57 weeks.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * 18-65 years * no hospitalization for an exacerbation of schizophrenia within two months prior to screening and during the screening period exclusion criteria: * subjects who are acutely psychotic or subjects with current axis i primary psychiatric diagnosis other than schizophrenia * at significant risk of suicide, and the potential for violent behavior (likely to harm themselves or others) based on history

Keywords: schizophrenia weight changes
integrated outpatient treatment of opioid use disorder and severe injection related infections

Conditions: Drug Use; Opioid-use Disorder

Summary: this study will assess the efficacy of an integrated outpatient treatment model for persons with opioid use disorder and injection related infections. the investigators hypothesize that outpatient antibiotic treatment coupled with comprehensive treatment for opioid use disorder will demonstrate a safe and effective way to manage patients. results could improve the current protocols for the treatment of individuals with opioid use disorder and severe infections.


Eligibility criteria:
inclusion criteria: * have opioid use disorder * have a severe injection related infection requiring antibiotics * willing to accept buprenorphine treatment * anticipated to be discharged home * require iv antibiotic therapy exclusion criteria: * stroke or cerebral mycotic aneurysms preventing aortic or mitral valve surgery * fungal valve ie * requiring in-patient rehabilitation * current pregnancy * hypersensitivity or allergy to buprenorphine * class iii or iv heart failure * end-stage liver or renal disease * any condition that may prevent the volunteer from safely participating in the study * self-report of desire to inject into the picc line * pending legal action that could interfere with study participation * unsafe or unstable environment precluding safe administration of iv antibiotics * living more than a 60 minute drive outside of lexington, ky

Keywords: buprenorphine outpatient parenteral antibiotic opat injection infectious endocarditis injection-related infection
iron isomaltide for iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; Iron-deficiency; Anemia

Summary: primary purpose： to evaluate the difference of hematopoietic response rate at 1 month after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma. secondary purpose: to evaluate the difference of hematopoietic response rate, tolerance, acute side effects, qualtiy of life at 2 months and 3 months after concurrent chemoradiotherapy between iron isomaltide and oral iron supplement for treating iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma.

iron-deficiency anemia patients with locally advanced nasopharyngeal carcinoma will be enrolled and receive iron isomaltide or oral iron supplement after randomised. the hematopoietic response rate, tolerance, acute side effects, qualtiy of life and long time survival would be evaluated.

Eligibility criteria:
inclusion criteria: * volunteer and sign the informed consent in person. * aged 18-65 * pathological diagnosis of non-keratinizing npc (differentiated or undifferentiated, as who ii, iii type). * clinical stage of iii-iva（8thajcc/uicc staging system） * complete induction chemotherapy and concurrent chemoradiotherapy. * with ecog score 0-1. * female subjects: surgical sterilization or postmenopausal patients, or agree to use a medical approved contraceptive measure such as intrauterine device (iud), contraceptives or condoms during the study period. * hgb \<130g/l(male)，hgb\<120g/l(female). * serum ferritin≤800ug/l。 * liver function: alt, ast \< 2.5 times the upper limit of normal (uln), total bilirubin \< 2.0 × uln; * renal function: serum creatinine \<1.5×uln. exclusion criteria: * recurrence or distant metastasis nasopharyngeal carcinoma. * keratinizing squamous cell carcinoma (who type i). * pregnant or breastfeeding women, who are in their childbearing years and have not used effective contraception. * previous or concurrently with other malignancies, exclude cured skin basal cell carcinoma and cervical carcinoma in situ. * patients with severely diminished functions of the heart, liver, lung, kidney and bone marrow; * serious, unmanaged medical conditions and infections. * those with other therapeutic contraindications. * use of other investigational medications or clinical studies concurrently. * refused or incapacity to sign the informed consent to participate in the study. * people having mental or personality disorders, disability, or limited civil capacity. * evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study. * hgb\>130g/l(male)，hgb \>120g/l(female). * received transfusion therapy before. * receipt of oral or iv iron supplements or esas up to 4 weeks before inclusion * ferritin \> 800 ng/ml * ongoing bleeding.

Keywords: nasopharyngeal carcinoma iron-deficiency anemia
intra-abdominal pressures during the spontaneous breathing trial

Conditions: Respiratory Failure

Summary: increased intra-abdominal pressure (iap) affects pulmonary dynamics. however, little is studied whether pulmonary dynamics affects iap. we hypothesize that the change of iap can also reflect the change of pulmonary dynamics. in this study, we choose patients who received spontaneous breathing trial to answer the hypothesis.

during the weaning process, we tapered down the respiratory support from mechanical ventilation and recruited respiratory muscles to work. previous study showed that transdiaphragmatic pressure was increasing while pressure support was reducing. however, the transdiaphragmatic pressure required invasive procedure to measure and not used frequently in weaning. iap reflects the pleural pressure. if the peep is not changed, change of iap is largely due to change of transpulmonary pressure. study aim: 1. to evaluate the patterns of change of iap during sbt 2. to predict success of sbt by the change of iap 3. to predict weaning outcome by the change of iap

Eligibility criteria:
inclusion criteria: * adult patients with endotracheal intubation in the intensive care unit * the clinical condition is considered to prepare for weaning assessment exclusion criteria: * tracheostomy * severe heart failure, heart disease or arrhythmia * upper airway obstruction related respiratory failure * poor cooperation due to agitation * no foley catheter in place or had been removed * baseline iap above 20 mmhg

Keywords: intra-abdominal pressure spontaneous breathing trail weaning
perioperative dexmedetomidine on postoperative delirium in patients with brain tumors

Conditions: Postoperative Delirium

Summary: neurosurgery is a risk factor for delirium. dexmedetomidine might reduce delirium by reducing neuroinflammation, improving postoperative analgesia and sleep quality. the the primary hypothesis is that perioperative administration of dexmedetomidine can reduce the incidence of postoperative delirium

the investigators will be required to attend the professional training before recruitment and strictly adhere to the study protocol. all the raw data will be recorded in the case report forms. data will be entered doubly performed by two investigators and monitored securely in an electronic database with password protection at the medical center. the data base will be locked after all data have been cleaned. all the original fles will be maintained in storage for 5 years after completion of the study.

Eligibility criteria:
inclusion criteria: * patients with temporal glioma scheduled for a elective craniotomy * age ≥18 years * obtain written informed consent. exclusion criteria: * patients with severe preoperative cognitive impairment * history of traumatic brain injury or previous neurosurgery * history of psychotropic medications * allergy to dexmedetomidine * pregnant or lactating women * history of obstructive sleep apnoea syndrome * severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block * severe hepatic dysfunction * severe renal dysfunction
effects of short-term therapeutic fasting on nausea and vomiting due to chemotherapy

Conditions: Nausea Post Chemotherapy; Vomiting

Summary: this study aims to estimate the effect of the practice of a short-term partial fasting compared to a usual alimentation on nausea and vomiting within 5 days after the start of a chemotherapy session on 2 successive chemotherapy courses (4 sessions of chemotherapy) in patients starting treatment with highly emetogenic chemotherapy (abvd or avd protocol).

patients in fasting arm will practice partial fasting during 3 days (d-1, d1 (d day of chemotherapy) and d2) following a food guide during 4 chemotherapy sessions. patients in usual alimentation arm will continue to take food as usual practice. in each arm, patients will be interviewed at each chemotherapy sessions about nausea and vomiting (number and intensity of nausea and vomiting, treatments taken). denutrition, quality of life improvement, compliance to partial fasting, treatment response will be evaluate too.

Eligibility criteria:
inclusion criteria: * patient starting a treatment by chemotherapy abvd or avd * patient affiliated to a social security scheme * patient who gives his informed consent before any procedure related to the study exclusion criteria: * patient with diabetes * patient with recent gastric ulcer * patient with low bmi (less than 18,5 for patients under 70 or less than 21 for patient over 70) * albuminemia \<35 * patient wiht loss weight \> 10% in 6 months * pregnant or lactating women * chronic alcoholism * unable to understand the objectives and risks of the study * patient with psychiatric desorder, under guardianship or under judicial protection * patient who cannot read
the role of extracellular ph on spermatozoa's directional movement in vitro

Conditions: Infertility

Summary: the purpose of this research project is to determine whether or not the directional movement of spermatozoa is influenced by a ph gradient by examining spermatozoa in vitro.


Eligibility criteria:
inclusion criteria: * normal semen sample